2023
Hepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancer
2020
Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients
Deig C, Trone K, Beneville B, Stratton A, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Attia F, Bassale S, Chen Y, Keith D, Chen E, Lopez C, Gilbert E, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e581-e582. DOI: 10.1016/j.ijrobp.2020.07.1786.Peer-Reviewed Original Research
2018
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rate
2008
Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Dobie S, Warren J, Matthews B, Schwartz D, Baldwin L, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112: 789-799. PMID: 18189291, PMCID: PMC3103394, DOI: 10.1002/cncr.23244.Peer-Reviewed Original ResearchConceptsStage II patientsRectal cancer patientsStage III patientsII patientsCancer patientsStage IIAdjuvant radiationAdjuvant therapyIII patientsGeneral populationStage II rectal cancer patientsLower cancer-related mortalityReceipt of chemoradiationCancer mortality riskCancer-related mortalityMultivariate logistic regressionAdjusted riskAdjuvant chemoradiationChemotherapy receiptSurgical resectionSurvival benefitSEER-MedicareTherapy adherencePatient groupRadiation therapy
2007
Reoperation as a Quality Indicator in Colorectal Surgery
Morris A, Baldwin L, Matthews B, Dominitz J, Barlow W, Dobie S, Billingsley K. Reoperation as a Quality Indicator in Colorectal Surgery. Annals Of Surgery 2007, 245: 73-79. PMID: 17197968, PMCID: PMC1867944, DOI: 10.1097/01.sla.0000231797.37743.9f.Peer-Reviewed Original ResearchConceptsColorectal cancer patientsPostoperative proceduresPatient characteristicsCancer patientsProcedural interventionColorectal cancer surgeryAcute medical conditionsSEER-Medicare databaseLength of stayIntermediate outcome measuresQuality Improvement ProgramNonfatal complicationsAdjusted riskBowel perforationEmergent admissionPostoperative complicationsPostoperative interventionsWound complicationsAbdominal infectionColorectal surgeryOrgan injuryProlonged hospitalizationCancer surgeryTumor characteristicsEarly mortality
2005
Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer
Mauchley D, Lynge D, Langdale L, Stelzner M, Mock C, Billingsley K. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. The American Journal Of Surgery 2005, 189: 512-517. PMID: 15862487, DOI: 10.1016/j.amjsurg.2005.01.027.Peer-Reviewed Original ResearchConceptsPreoperative CT scanningRoutine preoperative CT scanningColon cancer patientsCT scanningCancer patientsCT scanClinical utilityPreoperative computed tomography scanningMode of treatmentComputed tomography scanningNontherapeutic operationsConsecutive patientsClinical managementAlters treatmentPatientsColon cancerTomography scanningTreatment planningInstitutional costsScansTreatmentCost savingsCancer
2004
Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis
Morris A, Billingsley K, Baxter N, Baldwin L. Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis. JAMA Surgery 2004, 139: 151-155. PMID: 14769572, DOI: 10.1001/archsurg.139.2.151.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBlack PeopleCohort StudiesColectomyConfidence IntervalsCross-Sectional StudiesFemaleHealth Care SurveysHumansIncidenceLogistic ModelsMaleMiddle AgedNeoplasm StagingOdds RatioPostoperative ComplicationsProbabilityRectal NeoplasmsRisk FactorsSEER ProgramSex FactorsSocioeconomic FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsRectal cancer patientsRectal cancerCancer patientsRadiation therapyCross-sectional cohort studyRadiation treatmentRacial disparitiesEnd Results (SEER) databaseSphincter-sparing proceduresRectal cancer treatmentAdvanced disease stagePopulation-based dataDelivery of careSignificant racial disparitiesAdvanced diseaseAggressive screeningCohort studySurgical therapyPelvic cancerSurveillance EpidemiologyResults databaseTreatment disparitiesDisease stageMinority patientsSurgical care
2001
Argon plasma coagulation for rectal bleeding after prostate brachytherapy
Smith S, Wallner K, Dominitz J, Han B, True L, Sutlief S, Billingsley K. Argon plasma coagulation for rectal bleeding after prostate brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 636-642. PMID: 11597803, DOI: 10.1016/s0360-3016(01)01704-7.Peer-Reviewed Original ResearchConceptsArgon plasma coagulationSound Health Care SystemPersistent rectal bleedingRectal bleedingHealth care systemPlasma coagulationSupplemental external beam radiationVeterans AffairsCare systemDegree of proctitisProgressive tissue destructionExternal beam radiationFour-field techniqueProstate cancer patientsRectal V100Single gastroenterologistRadiation proctitisActive bleedingAPC therapyPersistent bleedingMost patientsSymptomatic patientsClinical courseCancer patientsComplete resolution